Compare GE Vernova Inc (GEV) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Vernova Inc vs IDEXX Laboratories, Inc. — how do they compare? GE Vernova Inc trades at $1,004.73 (market cap $266.16B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: GE Vernova Inc is far larger — about 6.6× IDEXX Laboratories, Inc.'s market cap, and GE Vernova Inc pays a 0.2% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold GE Vernova Inc for 36 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| GEV | IDXX | |
|---|---|---|
Market Cap | $266.16B | $40.43B |
Volume | 2,324,165 | 692,164 |
Sector | Industrials | Health |
52-Week High | $1.17K | $766.68 |
52-Week Low | $547.96 | $504.70 |
Typical Hold Time | 36 Days | 46 Days |
Enterprise Value | $255.83B | $41.32B |
Dividend Yield | 0.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) trades at $999.35, up 0.23% with strong bullish technical signals and positive analyst sentiment. The stock shows impressive fundamentals with 91.48% ROE and 23.04% net margin, though valuation metrics appear elevated with P/E of 28.65 and EV/EBITDA of 85.22. Recent news highlights the company securing the first US construction permit for its BWRX-300 small modular reactor and benefiting from AI-driven power demand growth.
GEV presents growth potential from its $176 billion backlog and AI infrastructure demand, but faces valuation concerns and execution risks in its wind power segment. Analyst consensus remains strongly bullish with 75.86% buy ratings and $1,270 price target, representing 27% upside from current levels. Key risks include competitive pressures and the challenge of maintaining current premium valuation multiples.
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
